Three words that send patients into a spiral of anxiety. Here’s what they actually mean, and what happens next.
You ordered the genetic test. You waited. The report arrived and somewhere in the middle of all the clinical language, three words jumped out at you:
“Variant of Uncertain Significance.”
Maybe your doctor explained it briefly. Maybe they said “don’t worry about it for now.” Maybe you went home and typed it into Google and immediately wished you hadn’t.
Whatever your experience, you are not alone. VUS results are one of the most common and most misunderstood findings in cancer genetic testing. And the anxiety they create is entirely understandable, because the name itself is unsettling.
So let’s break it down. Plainly. Honestly.
What a VUS Actually Is
Your DNA is made up of approximately 3 billion base pairs- the chemical letters that spell out your genetic code. In any one person, there are millions of natural variations in this sequence compared to the “reference” human genome. Most of these variations are completely harmless – the genetic equivalent of a different font, not a different word.
Genetic testing looks for specific changes- variants in cancer-related genes. When a variant is found, scientists compare it against vast databases of known genetic information to determine whether it is:
- Benign: known to be harmless
- Pathogenic: known to cause disease
- A Variant of Uncertain Significance – found, but not yet classified either way
A VUS is essentially a variant that science has not yet seen enough times; in enough people, with enough outcome data to confidently say whether it matters or not. It is not a diagnosis. It is not a red flag. It is, quite literally, an unanswered question.
But uncertainty has created more anxiety in humans and it always will.
How Common Are VUS Results?
Far more common than most patients expect.
In comprehensive genomic profiling– panels that test hundreds or thousands of genes simultaneously; VUS findings are almost inevitable. The more genes a panel tests, the more variants it finds, and the more of those variants fall into the uncertain category simply because the science hasn’t caught up yet.
Historically, managing VUS has been one of the most challenging parts of genomic medicine – for laboratories, for oncologists, and most of all for patients who are left waiting for an answer that may take years to arrive.
Because how can you treat a thing that you don’t know about?
The Three Things a VUS Is NOT
Before we go further, let’s give you some optimism and be direct about what a VUS result is not:
- It is not a cancer diagnosis. So, relax.
- Finding a VUS does not mean you have cancer or will develop it. So relax again.
- It is not a positive result.
A VUS is specifically not classified as pathogenic. It is in a separate, intermediate category precisely because it cannot be called harmful.
It is not permanent.
This is perhaps the most important thing to understand.
VUS classifications change, regularly. As more people are tested, as more data accumulates, as more families are studied; variants that were once uncertain get reclassified. Some are downgraded to benign. Some are upgraded to pathogenic. The science is always moving.
What Makes VUS Reclassification So Hard- And Why It’s Getting Easier:-
The challenge with VUS reclassification is that it requires evidence from multiple sources, and historically, those sources have been assessed separately, inconsistently, and slowly.
To confidently reclassify a VUS, scientists need to look at:
- In silico evidence – computational predictions of whether the variant damages protein function
- Evolutionary conservation – whether the affected DNA region is preserved across species (highly conserved regions are more likely to be functionally important)
- Functional studies – laboratory experiments testing whether the variant actually affects how the gene works
- Population databases – how rare the variant is across large groups of people
- Family history and co-occurrence – whether the variant appears alongside known pathogenic variants, or whether it tracks with cancer in families
- Clinical findings– what else is going on in the patient’s genome that might point in a consistent direction
Doing all of this manually, for every VUS in every patient, is time-consuming, inconsistent, and prone to human error.
This is exactly where AI is changing the game.
How AI Is Solving the VUS Problem
At 1Cell.Ai, our team presented research at AACR 2026 showing what happens when you apply a machine learning-based automated classification system to VUS interpretation- one that integrates all lines of evidence simultaneously rather than assessing them one by one.
In our study, several variants initially flagged as uncertain- intronic variants that had been sitting in the VUS category; were reclassified as likely pathogenic once our system integrated in silico evidence, evolutionary conservation scores, functional RNA data, and co-occurring genomic findings including high microsatellite instability and loss of MSH2 protein expression on IHC.
In one case, the system identified the presence of Lynch Syndrome – a hereditary cancer predisposition, that would likely have been missed by conventional single-database classification approaches. For that patient, a VUS that had offered no clinical guidance suddenly became an answer that changed their entire care plan and potentially their family members’ lives.
This is the power of multi-evidence integration. Not just looking at one signal, but synthesising all available signals into a coherent, biologically consistent clinical conclusion.
Our iCARE™ precision oncology console – part of our iCORE™ AI platform; incorporates AI-assisted variant classification as a core feature, bringing this level of analytical depth into the clinical workflow automatically, for every patient, every report.
What You Should Do If Your Report Contains a VUS
- Step 1: Don’t panic
I know, it’s easier said than done. But try to Remind yourself – a VUS is not a positive result. It is an unanswered question, not a diagnosis.
- Step 2: Ask your oncologist or genetic counsellor these questions:
- “Which gene was the VUS found in- and how relevant is that gene to my cancer type or family history?”
- “Has this variant been seen in other patients with similar presentations?”
- “How often does your lab re-evaluate VUS classifications as new data emerges?”
- “Should other family members be tested?
- Step 3: Make sure your VUS is being watched
Reputable laboratories and genomic platforms should proactively re-contact patients when a VUS is reclassified. Ask whether this is part of the accident because a VUS that becomes pathogenic in 18 months is information you deserve to receive automatically, not by accident.
- Step 4: Consider comprehensive profiling if you haven’t already
If your VUS was found on a single-gene or small-panel test, a broader comprehensive genomic profile may provide additional context- co-occurring findings, pathway-level signals, and population-level data, that helps reclassify the variant more quickly.
The VUS of Today May Be the Diagnosis of Tomorrow
Genetic science is moving fast. Variants that are uncertain today are being reclassified constantly as global genomic databases grow, as AI tools become more sophisticated, and as more families share their data for research.
A VUS in your report is not a closed door.
It is a door that science is still working to open, and the tools to open it faster are getting better every year.
At 1Cell.ai, our OncoIndx® panel and iCARE™ AI-assisted variant classification system are designed to give every VUS the multi-evidence scrutiny it deserves because “uncertain” should never be the last word in a patient’s genetic story.
